Capricor Therapeutics Inc (CAPR)

[mick]

$CAPR Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
GlobeNewswire
Capricor Therapeutics
,GlobeNewswire•September 23, 2020
--Final 12-Month Results from Phase II Trial to be Presented on October 1--


https://finance.yahoo.com/news/capricor-therapeutics-present-results-hope-132500199.html

--Final 12-Month Results from Phase II Trial to be Presented on October 1--

LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).

Dr. Craig McDonald, Study Chair of the CINRG Duchenne Natural History Study, as well as the National Principal Investigator for Capricor’s HOPE-2 study, along with Company management, will be available to discuss the e-poster at this year’s International World Muscle Society (WMS) Virtual Congress on October 1 from 12:30 to 2:30 p.m. ET.